Back to Search Start Over

Acquired Flucytosine Resistance during Combination Therapy with Caspofungin and Flucytosine for Candida glabrata Cystitis

Authors :
Anne Scemla
Christophe Legendre
Gilles Quesne
Emilie Sitterlé
Marie-Elisabeth Bougnoux
Caroline Charlier
Olivier Lortholary
Carine El Sissy
Sophie Bachelier-Bassi
Université Paris Descartes - Paris 5 (UPD5)
Biologie et Pathogénicité fongiques
Institut Pasteur [Paris]-Institut National de la Recherche Agronomique (INRA)
Service de transplantation rénale
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-CHU Necker - Enfants Malades [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Biologie et Pathogénicité fongiques (BPF)
Institut National de la Recherche Agronomique (INRA)-Institut Pasteur [Paris] (IP)
Source :
Antimicrobial Agents and Chemotherapy, Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2016, 60 (1), pp.662-665. ⟨10.1128/AAC.02265-15⟩, Antimicrobial Agents and Chemotherapy, 2016, 60 (1), pp.662-665. ⟨10.1128/AAC.02265-15⟩
Publication Year :
2015

Abstract

Treatment of Candida glabrata cystitis remains a therapeutic challenge, and an antifungal combination using flucytosine is one option. We describe two patients with refractory C. glabrata cystitis who failed flucytosine combined with caspofungin with early-acquired high-level resistance to flucytosine due to nonsense mutations in the FUR1 gene. Rapidly acquired flucytosine resistance with microbiological failure should discourage combination of caspofungin and flucytosine during urinary candidiasis.

Details

ISSN :
10986596 and 00664804
Volume :
60
Issue :
1
Database :
OpenAIRE
Journal :
Antimicrobial agents and chemotherapy
Accession number :
edsair.doi.dedup.....1f61ee4226d0ef662eca955b6abe712c